Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine
<i>Background and Objectives</i>: Three respiratory syncytial virus (RSV) vaccines have been recently made available for older adults. Understanding the principal characteristics of the first vaccine-takers can pave the way for a successful vaccination campaign. The objective of this stu...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/61/1/67 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587979621662720 |
|---|---|
| author | Alexander Domnich Andrea Orsi Piero Luigi Lai Elvira Massaro Carlo-Simone Trombetta Julieta Pastorino Charlott Roihl Marianna Pianta Giancarlo Icardi Donatella Panatto |
| author_facet | Alexander Domnich Andrea Orsi Piero Luigi Lai Elvira Massaro Carlo-Simone Trombetta Julieta Pastorino Charlott Roihl Marianna Pianta Giancarlo Icardi Donatella Panatto |
| author_sort | Alexander Domnich |
| collection | DOAJ |
| description | <i>Background and Objectives</i>: Three respiratory syncytial virus (RSV) vaccines have been recently made available for older adults. Understanding the principal characteristics of the first vaccine-takers can pave the way for a successful vaccination campaign. The objective of this study was to explore the sociodemographic and clinical characteristics of the first Italian users of an adjuvanted RSV vaccine and their attitudes towards RSV and vaccination. <i>Materials and Methods</i>: This cross-sectional study was conducted in 2024 in Liguria (Italy). Individuals aged ≥60 years with no contraindications to the adjuvanted vaccine RSVPreF3 OA were eligible. Following vaccination, subjects filled in a questionnaire, which comprised items on sociodemographic and clinical characteristics, attitudes towards RSV and RSV vaccination and a vaccination trust indicator (VTI). <i>Results</i>: A total of 453 vaccinees completed the survey. Their mean age was 74.9 ± 8.0 years, and 50.6% were males. Nine of ten (89.2%) individuals had ≥1 co-morbidity, of which cardiovascular conditions (70.4%), respiratory diseases (27.6%) and diabetes (18.5%) were the most common. Uptake of the routine vaccines was high: 91.2% and 98.7% received the 2023/2024 season influenza and ≥2 COVID-19 vaccines, respectively. The most common reasons for the current RSV vaccination were general practitioner advice (43.9%), followed by the willingness to be protected against (20.8%) and feelings of being at risk (16.6%) of RSV. The average VTI score was 91.5%, suggesting high trust in vaccines. More positive attitudes towards RSV vaccination were observed (<i>p</i> < 0.01) among subjects who received more COVID-19 vaccine doses, whose reasons for the current RSV vaccination were the willingness to be protected or to be in good health and the feeling of being at risk for RSV. <i>Conclusions</i>: The first Italian users of the novel RSVPreF3 OA vaccine were represented by high-risk individuals with a comparatively high prevalence of co-morbidities, high uptake of the seasonal respiratory vaccines and high trust in immunization. |
| format | Article |
| id | doaj-art-2e079698e56f4c6680b27db16fee1f22 |
| institution | Kabale University |
| issn | 1010-660X 1648-9144 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj-art-2e079698e56f4c6680b27db16fee1f222025-01-24T13:40:27ZengMDPI AGMedicina1010-660X1648-91442025-01-016116710.3390/medicina61010067Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) VaccineAlexander Domnich0Andrea Orsi1Piero Luigi Lai2Elvira Massaro3Carlo-Simone Trombetta4Julieta Pastorino5Charlott Roihl6Marianna Pianta7Giancarlo Icardi8Donatella Panatto9Hygiene Unit, San Martino Policlinico Hospital, IRCCS for Oncology and Neurosciences, 16132 Genoa, ItalyHygiene Unit, San Martino Policlinico Hospital, IRCCS for Oncology and Neurosciences, 16132 Genoa, ItalyDepartment of Health Sciences, University of Genoa, 16132 Genoa, ItalyDepartment of Health Sciences, University of Genoa, 16132 Genoa, ItalyDepartment of Health Sciences, University of Genoa, 16132 Genoa, ItalyDepartment of Health Sciences, University of Genoa, 16132 Genoa, ItalyDepartment of Health Sciences, University of Genoa, 16132 Genoa, ItalyDepartment of Health Sciences, University of Genoa, 16132 Genoa, ItalyHygiene Unit, San Martino Policlinico Hospital, IRCCS for Oncology and Neurosciences, 16132 Genoa, ItalyDepartment of Health Sciences, University of Genoa, 16132 Genoa, Italy<i>Background and Objectives</i>: Three respiratory syncytial virus (RSV) vaccines have been recently made available for older adults. Understanding the principal characteristics of the first vaccine-takers can pave the way for a successful vaccination campaign. The objective of this study was to explore the sociodemographic and clinical characteristics of the first Italian users of an adjuvanted RSV vaccine and their attitudes towards RSV and vaccination. <i>Materials and Methods</i>: This cross-sectional study was conducted in 2024 in Liguria (Italy). Individuals aged ≥60 years with no contraindications to the adjuvanted vaccine RSVPreF3 OA were eligible. Following vaccination, subjects filled in a questionnaire, which comprised items on sociodemographic and clinical characteristics, attitudes towards RSV and RSV vaccination and a vaccination trust indicator (VTI). <i>Results</i>: A total of 453 vaccinees completed the survey. Their mean age was 74.9 ± 8.0 years, and 50.6% were males. Nine of ten (89.2%) individuals had ≥1 co-morbidity, of which cardiovascular conditions (70.4%), respiratory diseases (27.6%) and diabetes (18.5%) were the most common. Uptake of the routine vaccines was high: 91.2% and 98.7% received the 2023/2024 season influenza and ≥2 COVID-19 vaccines, respectively. The most common reasons for the current RSV vaccination were general practitioner advice (43.9%), followed by the willingness to be protected against (20.8%) and feelings of being at risk (16.6%) of RSV. The average VTI score was 91.5%, suggesting high trust in vaccines. More positive attitudes towards RSV vaccination were observed (<i>p</i> < 0.01) among subjects who received more COVID-19 vaccine doses, whose reasons for the current RSV vaccination were the willingness to be protected or to be in good health and the feeling of being at risk for RSV. <i>Conclusions</i>: The first Italian users of the novel RSVPreF3 OA vaccine were represented by high-risk individuals with a comparatively high prevalence of co-morbidities, high uptake of the seasonal respiratory vaccines and high trust in immunization.https://www.mdpi.com/1648-9144/61/1/67respiratory syncytial virusRSVvaccinationRSV vaccineRSVPreF3 OAolder adults |
| spellingShingle | Alexander Domnich Andrea Orsi Piero Luigi Lai Elvira Massaro Carlo-Simone Trombetta Julieta Pastorino Charlott Roihl Marianna Pianta Giancarlo Icardi Donatella Panatto Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine Medicina respiratory syncytial virus RSV vaccination RSV vaccine RSVPreF3 OA older adults |
| title | Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine |
| title_full | Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine |
| title_fullStr | Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine |
| title_full_unstemmed | Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine |
| title_short | Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine |
| title_sort | characteristics of the first italian older adults vaccinated with an adjuvanted respiratory syncytial virus rsv vaccine |
| topic | respiratory syncytial virus RSV vaccination RSV vaccine RSVPreF3 OA older adults |
| url | https://www.mdpi.com/1648-9144/61/1/67 |
| work_keys_str_mv | AT alexanderdomnich characteristicsofthefirstitalianolderadultsvaccinatedwithanadjuvantedrespiratorysyncytialvirusrsvvaccine AT andreaorsi characteristicsofthefirstitalianolderadultsvaccinatedwithanadjuvantedrespiratorysyncytialvirusrsvvaccine AT pieroluigilai characteristicsofthefirstitalianolderadultsvaccinatedwithanadjuvantedrespiratorysyncytialvirusrsvvaccine AT elviramassaro characteristicsofthefirstitalianolderadultsvaccinatedwithanadjuvantedrespiratorysyncytialvirusrsvvaccine AT carlosimonetrombetta characteristicsofthefirstitalianolderadultsvaccinatedwithanadjuvantedrespiratorysyncytialvirusrsvvaccine AT julietapastorino characteristicsofthefirstitalianolderadultsvaccinatedwithanadjuvantedrespiratorysyncytialvirusrsvvaccine AT charlottroihl characteristicsofthefirstitalianolderadultsvaccinatedwithanadjuvantedrespiratorysyncytialvirusrsvvaccine AT mariannapianta characteristicsofthefirstitalianolderadultsvaccinatedwithanadjuvantedrespiratorysyncytialvirusrsvvaccine AT giancarloicardi characteristicsofthefirstitalianolderadultsvaccinatedwithanadjuvantedrespiratorysyncytialvirusrsvvaccine AT donatellapanatto characteristicsofthefirstitalianolderadultsvaccinatedwithanadjuvantedrespiratorysyncytialvirusrsvvaccine |